Skip to main content
Top
Published in: AIDS and Behavior 9/2021

01-09-2021 | Human Immunodeficiency Virus | Original Paper

Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention

Authors: Marla J. Husnik, Elizabeth R. Brown, Sufia S. Dadabhai, Zakir Gaffoor, Nitesha Jeenarain, Flavia Matovu Kiweewa, Edward Livant, Leila E. Mansoor, Brenda Gati Mirembe, Thesla Palanee-Phillips, Devika Singh, Samantha Siva, Lydia Soto-Torres, Ariane van der Straten, Jared M. Baeten, for the M. T. N.-020/ASPIRE Study Team

Published in: AIDS and Behavior | Issue 9/2021

Login to get access

Abstract

Understanding characteristics associated with adherence to pre-exposure prophylaxis (PrEP) methods for HIV-1 prevention may assist with optimizing implementation efforts. The dapivirine vaginal ring is a novel topical PrEP delivery method. Using data from a randomized, double-blind, placebo-controlled, phase III trial of the dapivirine vaginal ring conducted in four African countries, generalized estimating equation models were used to evaluate correlates of ring adherence. Two levels of quarterly dapivirine blood plasma, and dapivirine released from returned rings defined measures of adherence for recent and cumulative use, respectively. Time on study, calendar time, primary partner knowledge that the participant was taking part in the study, and use of long-acting contraceptive methods were associated with ring adherence whereas younger age, ring worries, condom use, episodes of menstrual bleeding and vaginal washing were associated with non-adherence. These findings may be useful for recruitment into future clinical studies and dapivirine ring implementation efforts.
Literature
3.
go back to reference Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.CrossRef Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.CrossRef
4.
go back to reference Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.CrossRef Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.CrossRef
5.
go back to reference Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRef Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRef
6.
go back to reference Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir based pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.CrossRef Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir based pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.CrossRef
7.
go back to reference Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRef Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRef
8.
go back to reference Rees H, Delany-Moretlwe S, Lombard C, et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women CROI 2015: presented at the conference on retroviruses and opportunistic infections, Boston, February 23–26, 2015. Abstract. Rees H, Delany-Moretlwe S, Lombard C, et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women CROI 2015: presented at the conference on retroviruses and opportunistic infections, Boston, February 23–26, 2015. Abstract.
9.
go back to reference Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–43.CrossRef Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–43.CrossRef
10.
go back to reference Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–32.CrossRef Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–32.CrossRef
12.
go back to reference Husnik MJ, Brown ER, Marzinke M, et al. Implementation of a novel adherence monitoring strategy in a phase III, blinded, placebo-controlled, HIV-1 prevention clinical trial. J Acquir Immune Defic Syndr. 2017;76:330–7.CrossRef Husnik MJ, Brown ER, Marzinke M, et al. Implementation of a novel adherence monitoring strategy in a phase III, blinded, placebo-controlled, HIV-1 prevention clinical trial. J Acquir Immune Defic Syndr. 2017;76:330–7.CrossRef
13.
go back to reference Seserko LA, Emory JF, Hendrix CW, et al. The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. Bioanalysis. 2013;5(22):2771–83.CrossRef Seserko LA, Emory JF, Hendrix CW, et al. The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. Bioanalysis. 2013;5(22):2771–83.CrossRef
14.
go back to reference Podsadecki TJ, Vrijens BC, Tousset EP, et al. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1—infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRef Podsadecki TJ, Vrijens BC, Tousset EP, et al. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1—infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRef
15.
go back to reference Nel A, Haazen W, Nuttall J, et al. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28(10):1479–87.CrossRef Nel A, Haazen W, Nuttall J, et al. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28(10):1479–87.CrossRef
16.
go back to reference Nel AM, Haazen W, Nuttall JP, et al. Pharmacokinetics and safety assessment of anti-HIV dapivirine vaginal microbicide rings with multiple dosing. J AIDS Clin Res. 2014;5:355. Nel AM, Haazen W, Nuttall JP, et al. Pharmacokinetics and safety assessment of anti-HIV dapivirine vaginal microbicide rings with multiple dosing. J AIDS Clin Res. 2014;5:355.
17.
go back to reference Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-Saharan Africa. PLoS ONE. 2016;11:e0147743.CrossRef Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-Saharan Africa. PLoS ONE. 2016;11:e0147743.CrossRef
18.
go back to reference Spence P, Nel A, van Niekerk N, et al. Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. J Pharm Biomed Anal. 2016;125:94–100.CrossRef Spence P, Nel A, van Niekerk N, et al. Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. J Pharm Biomed Anal. 2016;125:94–100.CrossRef
19.
go back to reference Brown ER, Hendrix CW, van der Straten A, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23:11. Brown ER, Hendrix CW, van der Straten A, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23:11.
20.
go back to reference Cohen R, Rodriguez R. "High-Performance Statistical Modeling". In: Proceedings of the SAS Global Forum Conference. Cary, NC: SAS Institute Inc; 2013 Cohen R, Rodriguez R. "High-Performance Statistical Modeling". In: Proceedings of the SAS Global Forum Conference. Cary, NC: SAS Institute Inc; 2013
21.
go back to reference Weinrib R, Minnis A, Agot K, et al. End-users’ product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South. AIDS Behav. 2018;22:133.CrossRef Weinrib R, Minnis A, Agot K, et al. End-users’ product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South. AIDS Behav. 2018;22:133.CrossRef
22.
go back to reference Montgomery ET, van der Straten A, Chitukuta M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159–67.CrossRef Montgomery ET, van der Straten A, Chitukuta M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159–67.CrossRef
23.
go back to reference Montgomery ET, van der Straten A, Cheng H, et al. Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 2012;7:1787–98.CrossRef Montgomery ET, van der Straten A, Cheng H, et al. Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 2012;7:1787–98.CrossRef
24.
go back to reference van der Straten A, Montgomery E, Cheng H, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16:1775–86.CrossRef van der Straten A, Montgomery E, Cheng H, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16:1775–86.CrossRef
25.
go back to reference Karim AQ, Karim AS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef Karim AQ, Karim AS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef
26.
go back to reference Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340–8.CrossRef Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340–8.CrossRef
27.
go back to reference Blanc AK, Tsui AO, Croft TN, Trevitt JL. Patterns and trends in adolescents’ contraceptive use and discontinuation in developing countries and comparisons with adult women. Int Perspect Sex Reprod Health. 2009;35:63–71.CrossRef Blanc AK, Tsui AO, Croft TN, Trevitt JL. Patterns and trends in adolescents’ contraceptive use and discontinuation in developing countries and comparisons with adult women. Int Perspect Sex Reprod Health. 2009;35:63–71.CrossRef
28.
go back to reference Evans D, Menezes C, Mahomed K, et al. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga. South Africa AIDS Res Hum Retroviruses. 2013;29:892–900.CrossRef Evans D, Menezes C, Mahomed K, et al. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga. South Africa AIDS Res Hum Retroviruses. 2013;29:892–900.CrossRef
29.
go back to reference van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.CrossRef van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.CrossRef
31.
go back to reference Browne EN, Mayo AJ, Montgomery E, et al. Acceptability of and adherence to the dapivirine vaginal ring for HIV 1 prevention. Adherence 2019, June 17, 2019, Miami, FL. Browne EN, Mayo AJ, Montgomery E, et al. Acceptability of and adherence to the dapivirine vaginal ring for HIV 1 prevention. Adherence 2019, June 17, 2019, Miami, FL.
32.
go back to reference van der Straten A, Browne E, Shapley-Quinn MK, et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81:304–10.CrossRef van der Straten A, Browne E, Shapley-Quinn MK, et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81:304–10.CrossRef
33.
go back to reference Duby Z, Katz AWK, Browne EN, et al. Hygiene, blood flow, and vaginal overload: why women removed an HIV prevention vaginal ring during menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2019;24:617–28.CrossRef Duby Z, Katz AWK, Browne EN, et al. Hygiene, blood flow, and vaginal overload: why women removed an HIV prevention vaginal ring during menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2019;24:617–28.CrossRef
34.
go back to reference Balkus JE, Palanee-Phillips T, Reddy K, et al. Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. Acquir Immune Defic Syndr. 2017;76:e47–51.CrossRef Balkus JE, Palanee-Phillips T, Reddy K, et al. Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. Acquir Immune Defic Syndr. 2017;76:e47–51.CrossRef
35.
go back to reference Mensch BS, Richardson BA, Husnik M, et al. Vaginal ring use in a phase 3 microbicide trial: a comparison of objective measures and self-reports of non-adherence in ASPIRE. AIDS Behav. 2019;23:504–12.CrossRef Mensch BS, Richardson BA, Husnik M, et al. Vaginal ring use in a phase 3 microbicide trial: a comparison of objective measures and self-reports of non-adherence in ASPIRE. AIDS Behav. 2019;23:504–12.CrossRef
Metadata
Title
Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention
Authors
Marla J. Husnik
Elizabeth R. Brown
Sufia S. Dadabhai
Zakir Gaffoor
Nitesha Jeenarain
Flavia Matovu Kiweewa
Edward Livant
Leila E. Mansoor
Brenda Gati Mirembe
Thesla Palanee-Phillips
Devika Singh
Samantha Siva
Lydia Soto-Torres
Ariane van der Straten
Jared M. Baeten
for the M. T. N.-020/ASPIRE Study Team
Publication date
01-09-2021
Publisher
Springer US
Published in
AIDS and Behavior / Issue 9/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03231-x

Other articles of this Issue 9/2021

AIDS and Behavior 9/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.